View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Vranken
Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
Delphine Brault ... (+2)
  • Delphine Brault
  • Steven Boumans
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Basic-Fit: Expands and extends banking facility. PostNL: USO mail proposal – step in right direction but timing late, no compensation. Umicore: Raises FY 2025 EBITDA guidance by c.9%

Martijn Den Drijver
  • Martijn Den Drijver
Jacob Mekhael ... (+6)
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste

Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONW...

: ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA

 PRESS RELEASE

dsm-firmenich announces redemption of €750 million hybrid bond

dsm-firmenich announces redemption of €750 million hybrid bond Press Release dsm-firmenich announces redemption of €750 million hybrid bond Kaiseraugst (Switzerland), Maastricht (Netherlands), July 1, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, has decided to call and redeem the €750 million Deeply Subordinated Fixed Rate Resettable Perpetual Loan Notes (the “hybrid bond”) issued on May 27, 2020 (XS2182055009) by Firmenich International SA (the “Issuer”), a direct subsidiary of DSM-Firmenich A.G. The €750 million hybrid bond, with a coupon of 3.75%, is treated as equ...

 PRESS RELEASE

Weekly progress on share repurchase program to cover share plans and r...

Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), July 1, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total amou...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ASR: Buyout deal, second in as many months, similar size (€660m). Flow Traders: Sticky digits. IMCD: Small but solid acquisition in India. Randstad: Preliminary preview of 2Q25F results due 23 July. UCB: Fintepla meets primary endpoint in CDKL5 Deficiency Disorder

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
Thomas Vranken
  • Thomas Vranken

UCB FIRST LOOK: Fintepla scores Phase 3 win in third epileptic indicat...

UCB announced positive Phase 3 results for Fintepla in treating CDKL5 deficiency disorder (CDD), a rare and severe early-onset epileptic condition with limited treatment options. The randomized, placebo-controlled study in patients aged 1–35 met its primary and secondary endpoints, showing a significant reduction in countable motor seizures and a favourable safety profile. UCB plans to announce the full dataset at an upcoming conference and seek regulatory approval promptly. This marks Fintepla'...

 PRESS RELEASE

dsm-firmenich announces increase in share repurchase program to reduce...

dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion Press Release dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 27, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital. This share repurchase program started for an initial €500 million and will now be increased to €1 billion, followin...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch